Integrating genomic-based clinical decision support into electronic health records

Personalized Medicine

Volumn 7, Issue 2, 2010, Pages 163-170

  Al Mallah, Amr ^a   Guelpa, Paul ^a   Marsh, Sharon ^a,b   Van Rooij, Tibor ^a  

^a MONTREAL HEART INSTITUTE   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Clinical decision support; Direct to consumer testing; Electronic health; Electronic health record; Genomics; Personal health record; Personalized medicine; Point of care; Standardization; Targeted therapeutics

Indexed keywords

CLINICAL DECISION MAKING; COST BENEFIT ANALYSIS; GENETIC ANALYSIS; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; INFORMATION PROCESSING; MEDICAL EDUCATION; MEDICAL ETHICS; PRIORITY JOURNAL; REVIEW; SOCIOECONOMICS;

EID: 77949677764     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.09.73     Document Type: Review

References (41)

1. McGlynn EA, Asch SM, Adams J et al.: The quality of health care delivered to adults in the United States. N. Engl. J. Med. 348(26), 2635-2645 (2003).
2. Sisko A, Truffer C, Smith S et al.: Health spending projections through 2018: recession effects add uncertainty to the outlook. Health Aff. (Millwood) 28(2), W346-W357 (2009).
3. Amarasingham R, Plantinga L, Diener-West M, Gaskin DJ, Powe NR: Clinical information technologies and inpatient outcomes: a multiple hospital study. Arch. Intern. Med. 169(2), 108-114 (2009).
4. Chaudhry B, Wang J, Wu S et al.: Systematic review: impact of health information technology on quality, efficiency and costs of medical care. Ann. Intern. Med. 144(10), 742-752 (2006).
5. Ford EW, Menachemi N, Peterson LT, Huerta TR: Resistance is futile: but it is slowing the pace of EHR adoption nonetheless. J. Am. Med. Inform. Assoc. 16(3), 274-281 (2009).
6. Jha AK, DesRoches CM, Campbell EG et al.: Use of electronic health records in US hospitals. N. Engl. J. Med. 360(16), 1628-1638 (2009).
7. ten Bosch JR, Grody WW: Keeping up with the next generation: massively parallel sequencing in clinical diagnostics. J. Mol. Diagn. 10(6), 484-492 (2008).
8. Steinbrook R: Health care and the American recovery and reinvestment act. N. Engl. J. Med. 360(11), 1057-1060 (2009).
9. Catz M, Bayne J: Canada health infoway - a pan-Canadian approach. AMIA Annu. Symp. Proc. 807 (2003).
10. Halamka JD, Mandl KD, Tang PC: Early experiences with personal health records. J. Am. Med. Inform. Assoc. 15(1), 1-7 (2008).
11. Osheroff JA, Teich JM, Middleton B, Steen EB, Wright A, Detmer DE: A roadmap for national action on clinical decision support. J. Am. Med. Inform. Assoc. 14(2), 141-145 (2007).
12. Kawamoto K, Lobach DF, Willard HF, Ginsburg GS: A national clinical decision support infrastructure to enable the widespread and consistent practice of genomic and personalized medicine. BMC Med. Inform. Decis. Mak. 9, 17 (2009).
13. Evans WE, McLeod HL: Pharmacogenomics - drug disposition, drug targets, and side effects. N. Engl. J. Med. 348(6), 538-549. (2003).
14. West M, Ginsburg GS, Huang AT, Nevins JR: Embracing the complexity of genomic data for personalized medicine. Genome Res. 16(5), 559-566 (2006).
15. Emery J, Walton R, Murphy M et al.: Computer support for interpreting family histories of breast and ovarian cancer in primary care: comparative study with simulated cases. BMJ 321(7252), 28-32 (2000).
16. Feero WG, Bigley MB, Brinner KM: New standards and enhanced utility for family health history information in the electronic health record: an update from the American health information community's family health history multi-stakeholder workgroup. J. Am. Med. Inform. Assoc. 15(6), 723-728 (2008).
17. Flockhart DA, Skaar T, Berlin DS, Klein TE, Nguyen AT: Clinically available pharmacogenomics tests. Clin. Pharmacol. Ther. 86(1), 109-113 (2009).
18. Eckman MH, Rosand J, Greenberg SM, Gage BF: Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann. Intern. Med. 150(2), 73-83 (2009).
19. Hughes DA, Vilar FJ, Ward CC, Alfirevic A, Park BK, Pirmohamed M: Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics 14(6), 335-342 (2004).
20. Innocenti F, Ratain MJ: Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping. Pharmacogenomics 7(8), 1211-1221 (2006).
21. Hoffman MA: The genome-enabled electronic medical record. J. Biomed. Inform. 40(1), 44-46 (2007).
22. Hoffman MA, Arnoldi C, Chuang I: The clinical bioinformatics ontology: a curated semantic network utilizing RefSeq information. Pac. Symp. Biocomput. 139-150 (2005).
23. Hillestad R, Bigelow J, Bower A et al.: Can electronic medical record systems transform health care? Potential health benefits, savings, and costs. Health Aff. (Millwood) 24(5), 1103-1117 (2005).
24. Blumenthal D, Glaser JP: Information technology comes to medicine. N. Engl. J. Med. 356(24), 2527-2534 (2007).
25. Emmer S, Allendorf L: The medicare prescription drug, improvement, and modernization act of 2003. J. Am. Geriatr. Soc. 52(6), 1013-1015 (2004).
26. Ford EW, Menachemi N, Phillips MT: Predicting the adoption of electronic health records by physicians: when will health care be paperless? J. Am. Med. Inform. Assoc. 13(1), 106-112 (2006).
27. Scheuner MT, de Vries H, Kim B, Meili RC, Olmstead SH, Teleki S: Are electronic health records ready for genomic medicine? Genet. Med. 11(7), 510-517 (2009).
28. Ahmadian L, De Keizer NF, Cornet R: The use of snomed CT for representing concepts used in preoperative guidelines. Stud. Health Technol. Inform. 150, 658-662 (2009).
29. Foxhall K: AHIC 2.0. The next generation of the American health information community is almost here, yet there are still many more questions than answers. Healthc. Inform. 24(11), 28 (2007).
30. Hunter AJ: The innovative medicines initiative: A pre-competitive initiative to enhance the biomedical science base of Europe to expedite the development of new medicines for patients. Drug Discov. Today 13(9-10), 371-373 (2008).
31. Hodgson J: 2 billion euro IMI launched with European pharma. Nat. Biotechnol. 26(7), 717-718 (2008).
32. Kabachinski J: What is health level 7? Biomed. Instrum. Technol. 40(5), 375-379 (2006).
33. El Fadly A, Daniel C, Bousquet C, Dart T, Lastic PY, Degoulet P: Electronic healthcare record and clinical research in cardiovascular radiology. HL7 CDA and CDISC ODM interoperability. AMIA Annu. Symp. Proc. 11, 216-220 (2007).
34. Dressler LG, Terry SF: How will GINA influence participation in pharmacogenomics research and clinical testing? Clin. Pharmacol. Ther. 86(5), 472-475 (2009).
35. Glaser J, Henley DE, Downing G, Brinner KM: Advancing personalized health care through health information technology: an update from the American health information community's personalized health care workgroup. J. Am. Med. Inform. Assoc. 15(4), 391-396 (2008).
36. Gatchel B, Eby C, Johnson J, Deych E, Rieder M: Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin. Pharmacol. Ther. 84(3), 326-331 (2008).
37. Farkas DH, Holland CA: Direct-to-consumer genetic testing: two sides of the coin. J. Mol. Diagn. 11(4), 263-265 (2009).
38. Javitt G, Katsanis S, Scott J, Hudson K: Developing the blueprint for a genetic testing registry. Public Health Genomics 13(2), 95-105 (2010).
39. Gurwitz D, Bregman-Eschet Y: Personal genomics services: whose genomes? Eur. J. Hum. Genet. 17(7), 883-889 (2009).
40. Patch C, Sequeiros J, Cornel MC: Genetic horoscopes: is it all in the genes? Points for regulatory control of direct-to-consumer genetic testing. Eur. J. Hum. Genet. 17(7), 857-859 (2009).
41. van Rooij T: Behind the PGx challenge: Biofx. Genome Technology, 19-20, July/August (2007).